Boehringer Ingelheim Advances Obesity Pipeline with Phase II Trial of Triple Receptor Agonist
Friday, July 17, 2026
Boehringer Ingelheim has started a Phase II clinical trial of BI 3034701, an investigational triple GLP-1/GIP/NPY2 receptor agonist, for the treatment of people with obesity and overweight.
The trial marks a significant step in the company's cardiometabolic and obesity research programme, which focuses on addressing obesity as a major contributor to cardiovascular, kidney and metabolic diseases.
BI 3034701 is being developed as a potential first-in-class therapy that targets three biological pathways by activating the GLP-1, GIP and NPY2 receptors. The approach is intended to regulate body weight and metabolism while exploring new mechanisms that may help address the complex nature of obesity.
While GLP-1 and GIP receptor activation is already associated with appetite control, weight management and metabolic regulation, the role of NPY2 receptor activation is still under investigation. Researchers are studying its potential to influence hunger signalling and other aspects of eating behaviour.
The decision to begin Phase II development follows positive Phase I results, in which BI 3034701 demonstrated a generally favourable safety and tolerability profile. The Phase II study will assess the therapy's safety, effectiveness and appropriate dosing in people living with obesity and overweight.
The programme forms part of Boehringer Ingelheim's wider obesity pipeline, which includes several investigational treatments targeting different biological pathways. These include survodutide, a dual glucagon/GLP-1 receptor agonist currently in Phase III development, along with other next-generation therapies, including oral treatment candidates, aimed at improving long-term management of obesity and related metabolic conditions.
Source: globenewswire.com
